Study | Annane et al. 2013[26] | Bouadma et al. 2010[27] | Hochreiter et al. 2009[28] | Jensen et al. 2011[29] | Nobre et al. 2008[30] | Schroeder et al. 2009[31] | Svoboda et al. 2007[32] |
---|---|---|---|---|---|---|---|
Design | RCT | RCT | RCT | RCT | RCT | RCT | RCT |
Setting | Surgical and medical ICU | Surgical and medical ICU | Surgical ICU | Surgical and medical ICU | Surgical and medical ICU | Surgical ICU | Surgical ICU |
Condition | Severe sepsis and septic shock | Septic shock | Severe sepsis | Severe sepsis and septic shock | Severe sepsis and septic shock | Severe sepsis | Severe sepsis |
Total number of included patients | 61 | 267 | 110 | 459 | 79 | 27 | 72 |
Number of patients | |||||||
PCT group/control group | 31/30 | 138/129 (septic shock) | 57/53 | 247/212 | 39/40 | 14/13 | 38/34 |
55/53 (positive blood culture) | |||||||
Hospital mortality | |||||||
Relative risk (95% CI) | 0.68 (0.30; 1.55) | NA | 1.00 (0.53; 1.86) | NA | 1.03 (0.46; 2.31) | 0.93 (0.23; 3.81) | NA |
Events PCT group/events control group | 7/10 | 15/14 | 9/9 | 3/3 | |||
28-day mortality | |||||||
Relative risk (95% CI) | NA | 1.15 (0.81; 1.63) | NA | 1.02 (0.80; 1.30) | 1.03 (0.43; 2.46) | NA | 0.69 (0.35; 1.36) |
Events PCT group/events control group | 48/39 (septic shock) | 90/76 | 8/8 | 10/13 | |||
Duration of antibiotic treatment, days | |||||||
PCT group/control group | 5/5 (median) | 9.8/12.8 (mean) (only positive blood culture) | 5.9/7.9 (mean) | NA | 6.0/9.5 (median) | 6.6/8.3 (mean) | NA |
Length of ICU stay, days | |||||||
PCT group/control group | 22/23 (median) | NA | 15.5/17.7 (mean) | 6.0/5.0 (median) | 4.0/7.0 (median) | 16.4/16.7 (mean) | 16.1/19.4 (mean) |
Length of hospital stay, days | |||||||
PCT group/control group | 27/33 (median) | NA | NA | 23.0/22.0 (median) | 17.0/23.5 (median) | NA | NA |
SOFA score | |||||||
PCT group/control group | 9.5/10 (median) | NA | 6.7/7.0 (mean) | NA | 6.4/6.6 (mean) | 7.3/8.3 (mean) | 7.9/9.3 (mean) |
8.5 to 11/8 to 11 (IQR) | 3.68/3.62 (SD) | 3.3/3.0 (SD) | 3.5/4.2 (SD) | 2.8/3.3 (SD) | |||
Medical patients, %* | 97% | 89% | 0% | 59% | NA | 0% | 0% |
Subgroup of study | No | Yes | No | Yes | No | No | No |
Duration of study, months | 36 | 12 | 15 | 29 | 15 | 7 | 29 |
Study protocol available | Yes | Yes | Yes | Yes | Yes | No | No |
Country | France | France | Germany | Denmark | Switzerland | Germany | Czech Republic |